Dec 13, 2016
NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction
NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono...
91
Dec 13, 2016
NCT02990338: Phase 3 - Isatuximab, Pomalidomide & Dex VS Pom & Dex in relapsed Myeloma (ICARIA-MM)
ICARIA Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory...
303
Dec 9, 2016
NCT02728102: Phase 2 - Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) Phase II Multicenter Trial of Single Autologous Hematopoietic...
134
Dec 9, 2016
NCT02655458: Phase 1 - Elotuzumab in Comb. With Auto transplant and Lenalidomide Maintenance in MM
The purpose of this study is to explore the combination of Elotuzumab in combination with autologous stem cell transplantation and...
234
Dec 9, 2016
NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401
CRB-401 NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma Study CRB-401...
438
Dec 9, 2016
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma Trial of...
83
Dec 9, 2016
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM A Study of PVX-410, a Cancer...
197
Dec 9, 2016
NCT02884102: MMRF Molecular Profiling Protocol - Multiple Myeloma Research Foundation
MMRF NCT02884102: MMRF Molecular Profiling Protocol Multiple Myeloma Research Foundation Sponsor: Multiple Myeloma Research Foundation...
256
Dec 9, 2016
NCT02833610: Phase 2 - A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
NCT02833610: Phase 2 - A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency This research study is studying a...
149
Dec 8, 2016
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
ELOQUENT-3 trial NCT02654132: Phase 2: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without...
307
Dec 8, 2016
NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
AMG 176 NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML AMG 176 First in Human Trial in...
231
Dec 8, 2016
NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs
NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a...
93
Dec 8, 2016
Myeloma Canada: Patient Handbook - Myeloma and the Kidney
Myeloma Canada: Patient Handbook - Myeloma and the Kidney https://myeloma.ca/pixms/uploads/serve/ckeditor/mc_kidney_booklet_en_02_2017_we...
57
Dec 8, 2016
International Myeloma Working Group Recs for Diagnosis & Manag. of Myeloma-Related Renal Impairment
J Clin Oncol; 2016 May International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal...
36
Dec 7, 2016
FDA Approved for RRMM: Daratumumab + Revlimid & Dex AND Daratumumab + Velcade & Dex
On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with...
178
Dec 7, 2016
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma...
173
Dec 3, 2016
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 This is a...
177
Dec 1, 2016
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma Establish the MTD of Lintuzumab-Ac225 as monotherapy...
65